JP2023109947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023109947A5 JP2023109947A5 JP2023085969A JP2023085969A JP2023109947A5 JP 2023109947 A5 JP2023109947 A5 JP 2023109947A5 JP 2023085969 A JP2023085969 A JP 2023085969A JP 2023085969 A JP2023085969 A JP 2023085969A JP 2023109947 A5 JP2023109947 A5 JP 2023109947A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- hours
- pharmaceutically acceptable
- pharmacologically active
- active form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 4
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 2
- 238000007922 dissolution test Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 229960001344 methylphenidate Drugs 0.000 claims 2
- 229960005343 ondansetron Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 claims 1
- 229960001033 methylphenidate hydrochloride Drugs 0.000 claims 1
- 229960000770 ondansetron hydrochloride Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562108616P | 2015-01-28 | 2015-01-28 | |
| US62/108,616 | 2015-01-28 | ||
| JP2020015828A JP6943994B2 (ja) | 2015-01-28 | 2020-01-31 | 神経精神系障害の治療のための組成物および方法 |
| JP2021147148A JP7288016B2 (ja) | 2015-01-28 | 2021-09-09 | 神経精神系障害の治療のための組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147148A Division JP7288016B2 (ja) | 2015-01-28 | 2021-09-09 | 神経精神系障害の治療のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023109947A JP2023109947A (ja) | 2023-08-08 |
| JP2023109947A5 true JP2023109947A5 (enExample) | 2023-10-19 |
| JP7594045B2 JP7594045B2 (ja) | 2024-12-03 |
Family
ID=56544502
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540782A Active JP6655090B2 (ja) | 2015-01-28 | 2016-01-28 | 神経精神系障害の治療のための組成物および方法 |
| JP2020015828A Active JP6943994B2 (ja) | 2015-01-28 | 2020-01-31 | 神経精神系障害の治療のための組成物および方法 |
| JP2021147148A Active JP7288016B2 (ja) | 2015-01-28 | 2021-09-09 | 神経精神系障害の治療のための組成物および方法 |
| JP2023085969A Active JP7594045B2 (ja) | 2015-01-28 | 2023-05-25 | 薬学的組成物 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540782A Active JP6655090B2 (ja) | 2015-01-28 | 2016-01-28 | 神経精神系障害の治療のための組成物および方法 |
| JP2020015828A Active JP6943994B2 (ja) | 2015-01-28 | 2020-01-31 | 神経精神系障害の治療のための組成物および方法 |
| JP2021147148A Active JP7288016B2 (ja) | 2015-01-28 | 2021-09-09 | 神経精神系障害の治療のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20170326127A1 (enExample) |
| EP (2) | EP3251699B1 (enExample) |
| JP (4) | JP6655090B2 (enExample) |
| KR (6) | KR20220071297A (enExample) |
| CN (2) | CN114146088A (enExample) |
| DK (1) | DK3251699T3 (enExample) |
| ES (1) | ES2985064T3 (enExample) |
| WO (1) | WO2016122218A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110719778B (zh) * | 2017-04-24 | 2024-06-18 | 才思治疗公司 | 用于治疗抑郁的组合物和方法 |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| KR102176538B1 (ko) | 2019-01-31 | 2020-11-09 | 한국과학기술연구원 | 항정신병성 약물 검출용 fret 바이오센서 및 이를 이용한 검출 방법 |
| JP2024508113A (ja) * | 2021-03-06 | 2024-02-22 | ユニヴェルシテートスピタル バーゼル | Ｌｓｄ用量を調節するためのジェノタイピング又はフェノタイピングの使用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| EP0840610A1 (en) * | 1995-07-14 | 1998-05-13 | Medeva Europe Limited | Composition comprising d-threo-methylphenidate and another drug |
| US6281207B1 (en) * | 1999-09-15 | 2001-08-28 | Reed Richter | Treatment of movement disorders by administration of mirtazapine |
| WO2003037313A2 (en) * | 2001-10-31 | 2003-05-08 | Recovery Pharmaceuticals, Inc. | Methods for the treatment of addiction |
| ES2314362T3 (es) | 2003-01-16 | 2009-03-16 | Acadia Pharmaceuticals Inc. | Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas. |
| CN101132777A (zh) * | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| US7686560B2 (en) * | 2005-12-08 | 2010-03-30 | Conestoga Cold Storage | Rack, conveyor and shuttle automated pick system |
| US7678808B2 (en) * | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| MX377802B (es) * | 2008-05-27 | 2025-03-11 | Intra Cellular Therapies Inc | Metodos y composiciones para trastornos del sueño y otros trastornos. |
| CN102170874A (zh) * | 2008-08-06 | 2011-08-31 | 高思福斯中心（控股）有限公司 | 治疗精神病学障碍的组合物和方法 |
| WO2013061161A2 (en) * | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
-
2016
- 2016-01-28 DK DK16743696.3T patent/DK3251699T3/da active
- 2016-01-28 KR KR1020227017187A patent/KR20220071297A/ko not_active Ceased
- 2016-01-28 KR KR1020197017975A patent/KR20190077590A/ko not_active Ceased
- 2016-01-28 EP EP16743696.3A patent/EP3251699B1/en active Active
- 2016-01-28 EP EP24169410.8A patent/EP4385575A3/en active Pending
- 2016-01-28 KR KR1020187003387A patent/KR101994596B1/ko active Active
- 2016-01-28 CN CN202111430366.9A patent/CN114146088A/zh active Pending
- 2016-01-28 KR KR1020217023520A patent/KR20210095734A/ko not_active Ceased
- 2016-01-28 KR KR1020207007722A patent/KR20200032759A/ko not_active Ceased
- 2016-01-28 JP JP2017540782A patent/JP6655090B2/ja active Active
- 2016-01-28 CN CN201680007760.2A patent/CN107206093A/zh active Pending
- 2016-01-28 KR KR1020167021256A patent/KR20160103548A/ko not_active Ceased
- 2016-01-28 ES ES16743696T patent/ES2985064T3/es active Active
- 2016-01-28 WO PCT/KR2016/000903 patent/WO2016122218A2/ko not_active Ceased
-
2017
- 2017-07-28 US US15/662,289 patent/US20170326127A1/en not_active Abandoned
-
2020
- 2020-01-31 JP JP2020015828A patent/JP6943994B2/ja active Active
- 2020-03-04 US US16/808,458 patent/US20200197383A1/en not_active Abandoned
-
2021
- 2021-09-09 JP JP2021147148A patent/JP7288016B2/ja active Active
-
2023
- 2023-03-15 US US18/121,626 patent/US12311056B2/en active Active
- 2023-05-25 JP JP2023085969A patent/JP7594045B2/ja active Active
-
2025
- 2025-04-09 US US19/174,320 patent/US20250255823A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023109947A5 (enExample) | ||
| JP6062465B2 (ja) | カルビドパ／レボドパ胃内滞留性薬物供給 | |
| US4309405A (en) | Sustained release pharmaceutical compositions | |
| JP2024113000A (ja) | Ｈｉｖ予防のためのカプシド阻害剤 | |
| CN110051638B (zh) | 包含双胍的延迟释放组合物 | |
| TWI468191B (zh) | 有機化合物之調配物 | |
| HU178867B (en) | Process for preparing synergetic analgetic composition containing nalbuphine and acetaminophene | |
| CN104349773A (zh) | 用于治疗代谢性病症的组合物和方法 | |
| JP2005512995A5 (enExample) | ||
| RU2010135831A (ru) | Способы, лекарственные формы и наборы для введения зипрасидона без пищи | |
| RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| CN107205969B (zh) | 糖尿病治疗用药物组合物 | |
| CN105338970B (zh) | 包含他达拉非和坦洛新的药物胶囊复合制剂 | |
| BRPI0610634A2 (pt) | combinação para a terapia de hiperplasia benigna da próstata | |
| JP5678088B2 (ja) | ４−メチルピラゾール製剤 | |
| JP2024522817A (ja) | フェニルピロールアミノグアニジン塩及び製剤 | |
| CN120112279A (zh) | 药物制剂及其用途 | |
| WO2021074284A1 (fr) | Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes | |
| RU2018104691A (ru) | Композиции с модифицированным высвобождением ницерголина | |
| JP7574204B2 (ja) | レボケトコナゾールによる疾患の処置方法 | |
| JP2022511673A (ja) | 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用 | |
| JP2009507850A5 (enExample) | ||
| JP2024084670A5 (enExample) | ||
| CN118922214A (zh) | Ntsr1靶向放射性药物及检查点抑制剂的组合疗法 | |
| JP2000239163A (ja) | 腸疾患の治療剤 |